ArticleMolecular biology reports2025
Personalized human umbilical cord mesenchymal stem cell-derived exosome pre-treatment based on the simulation of scar microenvironment characteristics: a promising approach for early scar treatment.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Therapeutic value of mesenchymal stem cell-derived extracellular vesicles in hypertrophic and keloid scars: a systematic review and meta-analysis.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundMesenchymal stem cells (MSCs) are essential for tissue repair and immunomodulation, primarily through their paracrine effects, which are influenced by the surrounding microenvironment. The observed heterogeneity in MSCs, arising from diverse sources and culture conditions, suggests that disease-specific microenvironments can modulate the paracrine effects of MSCs. This study proposes to simulate the scar microenvironment to pretreat MSCs, enabling them to produce anti-scar-specific exosomes, and to evaluate the effectiveness of these exosomes in reducing scars. The ultimate goal is to develop more effective strategies for scar treatment.
methodshUCMSCs were pretreated with inflammatory factors (IF) or scar tissue homogenate (STH), and their exosomes were isolated. This process yielded four types of exosomes: IF-Exos, STH-Exos, IF-STH-Exos and traditional exosomes (Tra-Exos). The impact of these exosomes on myofibroblasts and M1 macrophages were assessed through cell experiments. The anti-scar potential of these compounds was further evaluated in a rabbit ear scar model.
resultsCellular experiments demonstrated that IF-STH-Exos not only inhibited the proliferation and migration of myofibroblasts but also promoted the polarization of macrophages from the M1 to M2 phenotype. Compared with other exosome groups, the IF-STH-Exos significantly reduced scar formation, reduced epithelial thickness, promoted collagen retraction, suppressed angiogenesis, and decreased both inflammation and the M1/M2 macrophage ratio in vivo. Additionally, IF-STH-Exos regulated the expression of genes involved in anti-fibrotic pathways while suppressing those linked to fibrosis.
conclusionExosomes pretreated under simulated scar microenvironment conditions can effectively mitigate scar formation by reducing inflammation and promoting anti-fibrotic processes. This study provides a novel approach to clinical anti-scar treatment.
Indexed as
Identifiers
40699397What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.